Back to all papers

Lung Cancer and Thoracic Malignancies: Staging and Treatment Response.

October 12, 2026pubmed logopapers

Authors

Kiran MY,Ozkan ZG

Affiliations (2)

  • Department of Nuclear Medicine, Nigde Training and Research Hospital, Asagi Kayabasi, Hastaneler Caddesi, 51100 Merkez, Nigde, Turkey. Electronic address: [email protected].
  • Department of Nuclear Medicine, Istanbul University, Topkapi, Turgut Ozal Millet Caddesi, Fatih 34093, Istanbul, Turkey.

Abstract

This article reviews the clinical role of 18F-fluorodeoxyglucose PET/ computed tomography (CT) in lung cancer and selected thoracic malignancies, focusing on staging and treatment response assessment, while emphasizing major interpretation pitfalls. In lung cancer, emphasis is placed on nodal and metastatic staging, evaluation for recurrence, metabolic response criteria, quantitative PET parameters, and treatment-specific imaging considerations. Selected applications in thymic epithelial tumors and malignant pleural mesothelioma are also discussed. Emerging approaches, including somatostatin receptor PET, fibroblast activation protein inhibitor PET, PET/MR imaging, and artificial intelligence-based PET/CT analysis, are briefly summarized.

Topics

Lung NeoplasmsThoracic NeoplasmsPositron Emission Tomography Computed TomographyJournal ArticleReview

Ready to Sharpen Your Edge?

Subscribe to join 11k+ peers who rely on RadAISlice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.